Advertisement

Hypertension and Heart Failure

Prevention, Targets, and Treatment

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Cardiology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Benjamin E.J.
        • Muntner P.
        • Bittencourt M.S.
        Heart disease and stroke statistics-2019 update: a report from the American Heart Association.
        Circulation. 2019; 139: e56-e528
        • Levy D.
        • Larson M.G.
        • Vasan R.S.
        • et al.
        The progression from hypertension to congestive heart failure.
        JAMA. 1996; 275: 1557-1562
        • Whelton P.K.
        • Carey R.M.
        • Aronow W.S.
        • et al.
        2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary. a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Hypertension. 2018; 71: 1269-1324
        • Lloyd-Jones D.M.
        • Larson M.G.
        • Leip E.P.
        • et al.
        Lifetime risk for developing congestive heart failure: the Framingham Heart Study.
        Circulation. 2002; 106: 3068-3072
        • Pfeffer M.A.
        Heart failure and hypertension: importance of prevention.
        Med Clin North Am. 2017; 101: 19-28
        • Vasan R.S.
        • Levy D.
        The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview.
        Arch Intern Med. 1996; 156: 1789-1796
        • Bhuiyan T.
        • Maurer M.S.
        Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma.
        Curr Cardiovasc Risk Rep. 2011; 5: 440-449
        • Carnethon Mercedes R.
        • Pu J.
        • Howard G.
        • et al.
        Cardiovascular health in African Americans: a scientific statement from the American Heart Association.
        Circulation. 2017; 136: e393-e423
        • Vivo R.P.
        • Krim S.R.
        • Cevik C.
        • et al.
        Heart failure in Hispanics.
        J Am Coll Cardiol. 2009; 53: 1167-1175
        • Lloyd-Jones D.M.
        • Evans J.C.
        • Levy D.
        Hypertension in adults across the age spectrum: current outcomes and control in the community.
        JAMA. 2005; 294: 466-472
        • Levy D.
        • Anderson K.M.
        • Savage D.D.
        • et al.
        Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors: the Framingham Heart Study.
        Ann Intern Med. 1988; 108: 7-13
        • Eisenberg E.
        • Di Palo K.E.
        • Piña I.L.
        Sex differences in heart failure.
        Clin Cardiol. 2018; 41: 211-216
        • Bui A.L.
        • Horwich T.B.
        • Fonarow G.C.
        Epidemiology and risk profile of heart failure.
        Nat Rev Cardiol. 2010; 8: 30
        • Messerli F.H.
        • Rimoldi S.F.
        • Bangalore S.
        The transition from hypertension to heart failure: contemporary update.
        JACC Heart Fail. 2017; 5: 543-551
        • Sorrentino M.J.
        The evolution from hypertension to heart failure.
        Heart Fail Clin. 2019; 15: 447-453
        • Ganau A.
        • Devereux R.B.
        • Roman M.J.
        • et al.
        Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension.
        J Am Coll Cardiol. 1992; 19: 1550-1558
        • Wright J.W.
        • Mizutani S.
        • Harding J.W.
        Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies.
        Heart Fail Rev. 2008; 13: 367-375
        • de Simone G.
        • Gottdiener J.S.
        • Chinali M.
        • et al.
        Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study.
        Eur Heart J. 2008; 29: 741-747
        • Borlaug B.A.
        • Redfield M.M.
        Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum.
        Circulation. 2011; 123: 2006-2014
        • Jessup M.
        • Brozena S.
        Heart failure.
        New Engl J Med. 2003; 348: 2007-2018
        • Sciarretta S.
        • Palano F.
        • Tocci G.
        • et al.
        Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk.
        Arch Intern Med. 2011; 171: 384-394
        • Staessen J.A.
        • Wang J.-G.
        • Thijs L.
        Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.
        J Hypertens. 2003; 21: 1055-1076
        • Verdecchia P.
        • Angeli F.
        • Cavallini C.
        • et al.
        Blood pressure reduction and renin–angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
        Eur Heart J. 2009; 30: 679-688
        • Ettehad D.
        • Emdin C.A.
        • Kiran A.
        • et al.
        Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.
        Lancet. 2016; 387: 957-967
        • Wright Jr., J.T.
        • Williamson J.D.
        • Whelton P.K.
        • et al.
        • SPRINT Research Group
        A randomized trial of intensive versus standard blood-pressure control.
        N Engl J Med. 2015; 373: 2103-2116
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America.
        Circulation. 2017; 136: e137-e161
        • Vokó Z.
        • Bots M.L.
        • Hofman A.
        • et al.
        J-shaped relation between blood pressure and stroke in treated hypertensives.
        Hypertension. 1999; 34: 1181-1185
        • Farnett L.
        • Mulrow C.D.
        • Linn W.D.
        • et al.
        The J-curve phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous?.
        JAMA. 1991; 265: 489-495
        • Banach M.
        • Aronow W.S.
        Blood pressure j-curve: current concepts.
        Curr Hypertens Rep. 2012; 14: 556-566
        • Desai R.V.
        • Banach M.
        • Ahmed M.I.
        • et al.
        Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial).
        Am J Cardiol. 2010; 106: 221-227
        • Tsimploulis A.
        • Lam P.H.
        • Arundel C.
        • et al.
        Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction.
        JAMA Cardiol. 2018; 3: 288-297
        • Pinho-Gomes A.C.
        • Rahimi K.
        Management of blood pressure in heart failure.
        Heart. 2019; 105: 589-595
        • Davis B.R.
        • Piller L.B.
        • Cutler J.A.
        • et al.
        Role of diuretics in the prevention of heart failure: the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
        Circulation. 2006; 113: 2201-2210
        • Liebson P.R.
        • Grandits G.A.
        • Dianzumba S.
        • et al.
        Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS).
        Circulation. 1995; 91: 698-706
        • Colucci W.S.
        • Kolias T.J.
        • Adams K.F.
        • et al.
        Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.
        Circulation. 2007; 116: 49-56
        • Verdecchia P.
        • Sleight P.
        • Mancia G.
        • et al.
        Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment Study in ACE intolerant subjects with cardiovascular disease.
        Circulation. 2009; 120: 1380-1389
        • Investigators* S.
        Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.
        N Engl J Med. 1992; 327: 685-691
        • Bavishi C.
        • Messerli F.H.
        • Kadosh B.
        • et al.
        Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.
        Eur Heart J. 2015; 36: 1967-1973
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
        J Am Coll Cardiol. 2013; 62: e147-e239
        • Rosendorff C.
        • Black H.R.
        • Cannon C.P.
        • et al.
        Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention.
        Circulation. 2007; 115: 2761-2788
        • Bozkurt B.
        • Aguilar D.
        • Deswal A.
        • et al.
        Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association.
        Circulation. 2016; 134: e535-e578
        • Franciosa J.A.
        • Jordan R.A.
        • Wilen M.M.
        • et al.
        Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial.
        Circulation. 1984; 70: 63-68
        • Packer M.
        • Carson P.
        • Elkayam U.
        • et al.
        Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2).
        JACC Heart Fail. 2013; 1: 308-314
        • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
        Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT).
        JAMA. 2002; 288: 2981-2997
        • Cohn J.N.
        • Pfeffer M.A.
        • Rouleau J.
        • et al.
        Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
        Eur J Heart Fail. 2003; 5: 659-667
        • Vardeny O.
        • Claggett B.
        • Anand I.
        • et al.
        Incidence, predictors, and outcomes related to hypo-and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
        Circ Heart Fail. 2014; 7: 573-579
        • Georgiopoulou V.V.
        • Kalogeropoulos A.P.
        • Butler J.
        Heart failure in hypertension: prevention and treatment.
        Drugs. 2012; 72: 1373-1398
        • Oliva R.V.
        • Bakris G.L.
        Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors.
        J Am Soc Hypertens. 2014; 8: 330-339